POA Pharma Scandinavia

What POA Pharma Scandinavia does

POA Pharma Scandinavia AB is a privately held specialty pharmaceutical company headquartered in Birkerød, Denmark, and operating as a wholly owned subsidiary of Galen Limited (the founding member of the Almac Group, owned by the McClay Foundation). The company distributes, markets, and commercialises proprietary, generic, and rare-disease products across Northern Europe, with direct operations in the Nordics (Denmark, Finland, Norway, Sweden, Iceland), Germany, Austria, and the Netherlands, and was acquired by Galen in January 2020 in a multi-million pound transaction.

The portfolio is structured in two categories. The medical nutrition franchise targets inborn metabolic diseases with a branded line of phenylalanine-, methionine-, and branched-chain-amino-acid-free protein substitutes — including PKU EASY (Microtabs, Microtabs Plus, Tablets, Liquid, Shake & Go, and GO formats), HCU EASY, MSUD EASY, TYR EASY, and Citrulline EASY — built around a proprietary slow-release microtab formulation using an ethylcellulose matrix. The medicines franchise spans gastroenterology (Laxido), neurology (Akineton, Naltrexone), otolaryngology (Otazem, Cetraxal, Cetraxal Comp), acute and emergency care (Penthrox), cardiology (Minoxidil), and female care (Lansinoh, distributed in Denmark).

POA's business model combines direct B2B distribution to healthcare systems, hospitals, and pharmacies with an in-licensing and out-licensing strategy anchored by exclusive regional partnerships (notably Istituto Gentili and Laboratorios Salvat for Nordic distribution). Revenue is generated through product sales and licensing royalties. The company is privately held, does not disclose financial results, and operates at a headcount of 11–50 within a parent group of 7000+ employees across 18 global facilities, giving it access to capital, regulatory infrastructure, and commercial reach that would be unavailable to a standalone boutique of its scale.

Name

POA Pharma Scandinavia

Legal name

POA Pharma Scandinavia AB

Website

https://poapharma.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

POA Pharma Scandinavia AB is a specialty pharmaceutical subsidiary of Galen Limited (Almac Group) that distributes, markets, and licenses proprietary, generic, and rare-disease medicines and medical nutrition products across Northern Europe, with a focus on inborn metabolic disease franchises and multi-therapeutic-area distribution partnerships.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Medical Nutrition & Meal Replacement (RTD, Bars, Powders) (CRADAGAN)

Keywords

• Specialty pharmaceuticals
• Medical nutrition products
• Rare disease treatments
• Inborn metabolic diseases
• Pharmaceutical distribution

Headquarters

HQ city

Gothenburg

HQ country

Sweden

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Product Distribution: Distribution, marketing, and commercialisation of proprietary, generic, and rare disease products across Northern Europe. Revenue generated through sales of licensed pharmaceutical products to healthcare systems and providers.
2. Medical Nutrition Products: Sale of specialized metabolic disease nutrition products (PKU EASY product line) for dietary management of inborn metabolic conditions.
3. In-licensing and Out-licensing: The company secures exclusive distribution rights through in-licensing agreements (e.g., Istituto Gentili, Salvat) and commercializes its own products through out-licensing arrangements in international markets.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

POA Pharma Scandinavia AB is a specialty pharmaceutical company that distributes, markets, and commercialises proprietary, generic, and rare disease products across Northern Europe. Its portfolio spans medical nutrition products for inborn metabolic diseases (PKU EASY, HCU EASY, MSUD EASY, TYR EASY, Citrulline EASY), ENT treatments (Cetraxal, Cetraxal Comp, Otazem), acute care (Penthrox), gastroenterology (Laxido), neurology (Akineton, Naltrexone), cardiology (Minoxidil), and female care (Lansinoh). The company relies on in-licensing and out-licensing arrangements alongside its proprietary PKU EASY medical nutrition line.

Product overview

POA Pharma Scandinavia operates as a specialty pharmaceutical company distributing, marketing, and commercializing proprietary, generic, and rare disease products across Northern Europe. The product portfolio consists of two main categories: (1) Medicines including gastrointestinal products (Laxido®), neurological/psychiatric products (Akineton®, Naltrexone), otolaryngology ear drops (Otazem®, Cetraxal®, Cetraxal Comp®), acute care anesthesia (Penthrox®), and cardiology (Minoxidil); and (2) Medical Nutrition products specifically for inborn metabolic diseases (IMD) including the PKU EASY product line (Microtabs Plus, Microtabs, Liquid, Shake & Go, Tablets, GO), HCU EASY Tablets, MSUD EASY Tablets, TYR EASY Tablets, and Citrulline EASY Tablets. The company also distributes female care products (Lansinoh®).

Differentiator

Problem solved

Functional benefit

Brands

• PKU EASY: Product line for Phenylketonuria dietary management including Microtabs, Microtabs Plus, Tablets, Liquid, Shake & Go, and GO formats.
• HCU EASY
• MSUD EASY
• TYR EASY
• Citrulline EASY

Products and services

• PKU EASY Microtabs Plus Phenylalanine-free protein substitute in small coated slow-release tablets containing vitamins, minerals, and essential/non-essential amino acids for dietary management of Phenylketonuria (PKU) in patients aged 3 years and above.
• PKU EASY Microtabs Small slow-release tablets containing essential and non-essential amino acids for dietary management of PKU in patients aged 3 years and above.
• PKU EASY Liquid Mixed Berry Ready-to-drink flavoured phenylalanine-free protein substitute containing amino acids, carbohydrates, vitamins, minerals, trace elements, and DHA omega-3 fatty acid for PKU patients aged 3 years and above.
• PKU EASY Shake & Go (Orange) Phenylalanine-free protein substitute powder in orange flavour for dietary management of PKU in patients aged 3 years and above.
• PKU EASY Shake & Go (Unflavoured) Unflavoured phenylalanine-free protein substitute powder for dietary management of PKU in patients aged 3 years and above.
• PKU EASY Tablets Phenylalanine-free protein substitute tablets for dietary management of PKU in patients aged 3 years and above.
• PKU GO 10p Phenylalanine-free protein substitute sachets (20g) containing amino acids, carbohydrates, vitamins, minerals, and trace elements for PKU dietary management in children from 9 months to 10 years.
• PKU GO 5p Phenylalanine-free protein substitute sachets (10g) for PKU dietary management in children from 9 months to 10 years.
• HCU EASY Tablets Methionine-free slow-release amino acid tablets for dietary management of Homocystinuria (HCU) in patients aged 3 years and above.
• MSUD EASY Tablets Leucine, isoleucine, and valine-free protein substitute tablets for dietary management of Maple Syrup Urine Disease (MSUD) in patients aged 3 years and above.
• TYR EASY Tablets Tyrosine and phenylalanine-free protein substitute tablets for dietary management of Tyrosinemia (TYR) in patients aged 3 years and above.
• Citrulline EASY Tablets L-citrulline amino acid supplement tablets for dietary management of Urea Cycle Disorders (UCDs) in patients over 3 years and adults.
• Laxido Apelsin Macrogol 3350-based powder for oral solution used for treating constipation.
• Laxido Junior Pediatric formulation of Macrogol 3350 powder for oral solution for constipation in children.
• Akineton Biperiden-based product available in 2mg tablets and 5mg/ml injection for treatment of Parkinson's disease.
• Otazem 250 micrograms/ml ear drops Fluocinolone acetonide-based ear drops for otolaryngology treatment.
• Naltrexone POA Pharma 50 mg film-coated tablets Naltrexone hydrochloride 50mg film-coated tablets for specialty care.
• Cetraxal 2 mg/ml ear drops solution Ciprofloxacin-based ear drops for treatment of ear infections in otolaryngology.
• Cetraxal Comp 3 mg/ml + 0.25 mg/ml ear drops solution Combination ciprofloxacin/fluocinolone acetonide ear drops for otolaryngology treatment.
• Penthrox Methoxyflurane 99.9% inhalation vapor, 3ml liquid for acute and emergency care pain management.
• Minoxidil POA Pharma Tablets Minoxidil tablets available in 2.5mg or 10mg dosages for hypertension treatment.
• Lansinoh Lansinoh breastfeeding and female care products distributed by POA Pharma in Denmark.

Quantifiable outcome

• Expanded Nordic portfolio through partnership with Istituto Gentili covering Denmark, Finland, and Norway
• +2 more outcomes

Named customers7 records

Segments7 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Istituto GentilicoreChannel Partner/ Reseller/ Distributor · 16 April 2026Licensing partnership under which POA Pharma Scandinavia assumes exclusive distribution responsibilities across Denmark, Finland, and Norway for a medication used in paediatric care. The partnership supports continuity of supply for healthcare professionals and patients in Nordic markets.
• Laboratorios Salvat, S.A.coreChannel Partner/ Reseller/ Distributor · 17 February 2026Exclusive licence and supply agreement marking an important expansion of POA's ENT portfolio in the Nordics. This agreement reinforces the long-standing collaborative relationship that has supported success of both organisations for many years.
• Penlan Healthcare LimitedminorChannel Partner/ Reseller/ Distributor · 19 September 2022Exclusive in-licensing agreement with Penlan Healthcare Limited for Rapilose Oral Glucose Solution (OGS) for entry into German market. Galen Limited had an existing long-standing in-licensing relationship with Penlan.
• Galen LimitedcoreStrategic or Co-development PartnerPOA Pharma is a subsidiary of Galen Limited, part of the Almac Group. This relationship provides resources to deliver high-quality products and services to patients in Germany, Austria, Netherlands, and Nordic region. Galen Limited was founded in 1968 by Sir Allen McClay.
• Almac GroupcoreStrategic or Co-development PartnerGalen Limited is a founding member of Almac Group. Almac is an established contract development and manufacturing organisation providing extensive services across the drug development lifecycle. The group employs over 7000 personnel across 18 facilities globally.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Alexion (AstraZeneca Rare Disease): Global rare disease pharmaceutical company (acquired by AstraZeneca) focused on metabolic and genetic conditions; large specialty pharma competitor serving overlapping rare disease patient populations with significant European commercial infrastructure.
• Mead Johnson Nutrition (Reckitt): Major pediatric and medical nutrition company (now part of Reckitt) with metabolic disease formulas including PKU products; large incumbent with broader infant nutrition portfolio competing in the medical nutrition space.
• Nestlé Health Science: Global medical nutrition business with substantial rare metabolic disease exposure including Vitaflo; broader portfolio across multiple therapeutic areas positions Nestlé Health Science as a large incumbent comparable to POA Pharma's specialty nutrition focus.
• Nutricia (Danone): Global leader in medical nutrition including extensive metabolic disease portfolio (PKU Anamix, MSUD, HCU products); a much larger incumbent offering broader nutritional products with overlapping IMD offerings to the same healthcare professional and patient base.
• Abbott Nutrition: Major medical nutrition manufacturer with established PKU and other metabolic disease formulas (e.g., Phenyl-Free); large multinational healthcare company with broader nutrition portfolio serving the same patient populations.

Direct peers

• Recordati Rare Diseases: European rare disease specialty pharmaceutical division of Recordati Group distributing treatments for rare conditions across multiple European markets; comparable specialty pharma distribution model focused on rare disease therapeutics.
• BioMarin Pharmaceutical: Rare disease specialty pharmaceutical company with direct PKU franchise (Palynziq/pegvaliase, Kuvan/sapropterin); competes in the same Phenylketonuria treatment market that POA Pharma addresses with PKU EASY medical nutrition products.
• Swedish Orphan Biovitrum (Sobi): Nordic-headquartered specialty pharmaceutical company focused on rare diseases with strong presence across Sweden, Denmark, Norway, Finland, and broader Northern Europe — comparable business model serving rare disease patient populations in the same geographies.
• Vitaflo: UK-based medical nutrition company (part of Nestlé Health Science) specializing in protein substitutes and dietary management products for inborn metabolic diseases including PKU, MSUD, HCU, TYR, and UCDs — direct product overlap with POA Pharma's EASY product line for the same patient populations.

Others

• Galen Limited: Direct parent company of POA Pharma providing the medical nutrition products (PKU EASY line via Galen Medical Nutrition) and operational backbone; included as a related-party ecosystem participant rather than a competitive peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/poapharma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about POA Pharma Scandinavia